Wednesday, August 30, 2017

Scythian Biosciences Corp. (TSXV: $SCYB.V) Applies for Listing of Common Stock on NASDAQ

Scythian Biosciences Corp. (TSXV: $SCYB.V) Applies for Listing of Common Stock on NASDAQ



TORONTO - August 30, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (TSXV: SCYB) (the "Company") is pleased to announce that it has submitted an initial listing application to list its common shares on the NASDAQ Capital Market.

The Company's common shares have traded on the TSX Venture Exchange (the "TSXV") under the symbol "SCYB" since August 8, 2017.

Read this news in full at

Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp


Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country

Tuesday, August 29, 2017

Concussion and TBI Treatment Company Scythian Biosciences (TSX.V: $SCYB.V) Retains The Weinberg Group for FDA IND and IND Consulting Services

Concussion and TBI Treatment Company Scythian Biosciences (TSX.V: $SCYB.V) Retains The Weinberg Group for FDA IND and IND Consulting Services



TORONTO - August 29, 2017 (Investorideas.com Newswire)   FDA news - Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) reports  it has entered into a consulting arrangement with The Weinberg Group and has retained The Weinberg Group's services for assistance with the Company's FDA application process, including pre-IND and IND consulting services.

Read this news in full at

Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country

Monday, August 28, 2017

Scythian Biosciences Corp. (TSX.V: $SCYB.V) Retains The Weinberg Group To Provide FDA Consulting Services

Scythian Biosciences Corp. (TSX.V: $SCYB.V) Retains The Weinberg Group To Provide FDA Consulting Services



TORONTO - August 28, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company") (
TSXV: SCYB) is pleased to announce that it has entered into a consulting arrangement with The Weinberg Group and has retained The Weinberg Group's services for assistance with the Company's FDA application process, including pre-IND and IND consulting services.

Read this news in full at

About Scythian Biosciences Corp.
Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp


Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country

Friday, August 18, 2017

Video News; Scythian Biosciences (TSX.V: $SCYB.V) Discusses #Cannabinoid-based Treatment for #Concussion and Traumatic Brain Injury

Video News; Scythian Biosciences (TSX.V: $SCYB.V) Discusses #Cannabinoid-based Treatment for #Concussion and Traumatic Brain Injury

August 18, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks releases a video/ interview featuring David Schrader, Chief Operating Officer of Scythian Biosciences (TSX.V: SCYB), a company developing a drug regimen for concussion and traumatic brain injury using a cannabinoid-based combination drug therapy.











Scythian ( http://scythianbio.com/) is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.


The Investorideas.com podcasts are also available on iTunes, Tunein, Sticher. Spreaker.com, iHeart.com  and Google Play Music.
Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/

Subscribe to Investorideas.com Podcast RSS:

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Visit Scythian Biosciences (TSX.V: SCYB  )Profile page: http://www.investorideas.com/CO/SCYB/

Contact Investorideas.com
800-665-0411



Thursday, August 17, 2017

Scythian Biosciences Corp. (TSXV: $SCYB.V) Retains Hybrid Financial Ltd. for Investor Relations Activities

Scythian Biosciences Corp. (TSXV: $SCYB.V) Retains Hybrid Financial Ltd. for Investor Relations Activities



TORONTO - August 17, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) announces that it has retained the services of Hybrid Financial Ltd. ("Hybrid Financial") for strategic investor relations activities. The initiatives includes marketing and investor relations services for the Company.


About Scythian Biosciences Corp.
Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Wednesday, August 16, 2017

COO of Scythian Biosciences (TSX.V: $SCYB.V) Talks about Treatment for #Concussion and traumatic brain injury with #Cannabinoid-based combination drug therapy

COO of Scythian Biosciences (TSX.V: $SCYB.V) Talks about Treatment for #Concussion and traumatic brain injury with  #Cannabinoid-based combination drug therapy


August 16, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues a  podcast interview with David Schrader, Chief Operating Officer at Scythian Biosciences Corp. (TSXV: SCYB).

Listen to the full podcast interview :

Read this news in full at


Scythian ( http://scythianbio.com/)  is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

The Investorideas.com podcasts are also available on iTunes, Tunein, Sticher. Spreaker.com, iHeart.com  and Google Play Music.
Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/

Subscribe to Investorideas.com Podcast RSS:

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details -http://www.investorideas.com/About/News/Clientspecifics.asp


Contact Investorideas.com
800-665-0411

Tuesday, August 15, 2017

Audio Interview with David Schrader, Chief Operating Officer at Scythian Biosciences (TSX.V: $SCYB.V)

Audio Interview with David Schrader, Chief Operating Officer at Scythian Biosciences (TSX.V: $SCYB.V)



August 15, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues an exclusive podcast interview with David Schrader, Chief Operating Officer at Scythian Biosciences Corp.  (TSX.V: SCYB).

Scythian Biosciences Corp. seeks to develop the first accepted drug regimen for concussion and traumatic brain injury with their cannabinoid-based combination drug therapy.

Read this news in full at
  
Listen to the full podcast interview :



Scythian ( http://scythianbio.com/)  is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

The Investorideas.com podcasts are also available on iTunes, Tunein, Sticher. Spreaker.com, iHeart.com  and Google Play Music.
Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/

Subscribe to Investorideas.com Podcast RSS:

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details -http://www.investorideas.com/About/News/Clientspecifics.asp


Contact Investorideas.com
800-665-0411

Monday, August 7, 2017

Concussion-focused Scythian (TSXV: $SCYB,V) sets market debut

Concussion-focused Scythian  (TSXV: $SCYB,V) sets market debut on the TSX Venture Exchange
The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets.

Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of the company’s outstanding shares, with the rest locked in escrow by the TSX Venture Exchange.
http://www.innovateli.com/concussion-focused-scythian-sets-stock-market-debut/